Aromatase catalyses the conversion of androgens into estrogens and is a well-known target for breast cancer therapy. As it has been suggested that its activity is affected by inhibitors of phosphodiesterase-5, this work investigates the potential interaction of sildenafil with aromatase. This is carried out both at molecular level through structural and kinetics assays applied to the purified enzyme, and at cellular level using neuronal and breast cancer cell lines. Sildenafil is found to bind to aromatase with a KD of 0.58±0.05μM acting as a partial and mixed inhibitor with a maximal inhibition of 35±2%. Hyperfine sublevel correlation spectroscopy and docking studies show that sildenafil binds to the heme iron via its 6th axial water ligand. These results also provide information on the starting molecular scaffold for the development of new generations of drugs designed to inhibit aromatase as well as phosphodiesterase-5, a new emerging target for breast cancer therapy.

Effect of sildenafil on human aromatase activity: From in vitro structural analysis to catalysis and inhibition in cells

BARAVALLE, ROBERTA;VALETTI, Francesca;CATUCCI, GIANLUCA;GAMBAROTTA, Giovanna;CHIESA, Mario;MAURELLI, SARA;GIAMELLO, Elio;DI NARDO, Giovanna
Co-last
;
GILARDI, Gianfranco
Co-last
2017

Abstract

Aromatase catalyses the conversion of androgens into estrogens and is a well-known target for breast cancer therapy. As it has been suggested that its activity is affected by inhibitors of phosphodiesterase-5, this work investigates the potential interaction of sildenafil with aromatase. This is carried out both at molecular level through structural and kinetics assays applied to the purified enzyme, and at cellular level using neuronal and breast cancer cell lines. Sildenafil is found to bind to aromatase with a KD of 0.58±0.05μM acting as a partial and mixed inhibitor with a maximal inhibition of 35±2%. Hyperfine sublevel correlation spectroscopy and docking studies show that sildenafil binds to the heme iron via its 6th axial water ligand. These results also provide information on the starting molecular scaffold for the development of new generations of drugs designed to inhibit aromatase as well as phosphodiesterase-5, a new emerging target for breast cancer therapy.
165
B
438
447
http://www.sciencedirect.com/science/article/pii/S0960076016302394
Aromatase inhibitors; Breast cancer; Cytochromes P450; Estrogens; Sildenafil
Baravalle, Roberta; Valetti, Francesca; Catucci, Gianluca; Gambarotta, Giovanna; Chiesa, Mario; Maurelli, Sara; Giamello, Elio; Barone, Ines; Catalano, Stefania; Andò, Sebastiano; Di Nardo, Giovanna; Gilardi, Gianfranco
File in questo prodotto:
File Dimensione Formato  
Baravalle-et-al-hltd-rev 2_4aperto.pdf

Accesso aperto

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 4.47 MB
Formato Adobe PDF
4.47 MB Adobe PDF Visualizza/Apri
1-s2.0-S0960076016302394-main.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 1.52 MB
Formato Adobe PDF
1.52 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1596231
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact